Tamiflu review raises questions

A systematic review of Roche's antiviral drug Tamiflu appearing in last month's Cochrane Library has led to questions about the data's efficacy, as well as Roche's commitment to provide sufficient data.

“We found a high risk of publication and reporting biases in the trial programme of [Tamiflu],” Cochrane Collaboration researchers wrote.

Evidence confirms Tamiflu shortened length of symptoms vs. placebo. Other findings question its mechanism of action but could not be properly assessed without access to the full document set. The paper “has raised challenges for all those engaged in conducting systematic reviews,” wrote Cochrane editors.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.